Navigation Links
ViewPoint CK System (Conductive Keratoplasty)

ProductsViewPoint CK System (Conductive Keratoplasty)
Company Refractec, Inc.
Item ViewPoint CK System (Conductive Keratoplasty)
Features Presbyopic Indications
Approval of the premarket approval application supplement for the Refractec ViewPoint CK System is for the temporary induction of myopia (-1.00 D to -2.00 D) to improve near vision in the non-dominant eye of presbyopic hyperopes or presbyopic emmetropes, via spherical hyperopic treatment of 1.00 D to 2.25 D, in patients 40 years of age or greater with a documented stability of refraction for the prior 12 months, as demonstrated by a change of < 0.50 D in spherical and cylindrical components of the manifest refraction, and with = 0.75 D of cycloplegic refractive cylinder and with a successful preoperative trial of monovision or history of monovision wear (i.e., dominant eye corrected for distance vision and non-dominant eye corrected for near vision).

Hyperopic Indications
The Refractec ViewPoint CK System is for the temporary reduction of spherical hyperopia in patients who have 0.75 D to 3.25 D of cycloplegic spherical hyperopia, less than or equal to 0.75 D of refractive astigmatism (minus cylinder format), and a cycloplegic spherical equivalent of +0.75 D to +3.00 D. Patients must be 40 years of age or greater with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than 0.50 D in spherical and cylindrical components of manifest refraction. The magnitude of correction with this treatment diminishes over time, with some patients retaining some or all of their intended refractive correction.

Description NearVision™ CK is the only procedure designed for patients with a spherical hyperopia between +0.75 D and +3.00 D or presbyopic patients who would benefit from a spherical treatment of between 1.00 D and 2.25 D to achieve a myopic endpoint of between -1.00 D and -2.00 D in their non-dominant eye to temporarily improve near vision. CK is unique in that it uses radiofrequency (RF) instead of a laser. It takes as little as three minutes and can be conveniently performed in-office using the ViewPoint CK System.

NearVision CK builds upon the principles of thermokeratoplasty, using radiofrequency (RF) energy to temporarily reshape the cornea and therefore adjust its refractive characteristics.

RF energy and its application
To perform the procedure, a handpiece with a Keratoplast™ Tip delivers controlled RF energy directly to the internal corneal tissue in a ring pattern. The tip serves as an RF antenna while the speculum holding the eye open serves as the return path. By applying RF energy to the tissue, Ohm's law (V = I R) defines a consistent relationship that determines the heat generated. The voltage (V) determines the electrical field strength within the tissue while the current (I) is defined by the treatment parameters. Impedance is a characteristic of tissue.

The characteristics of the energy (i.e., current, waveform, frequency, rep rate and crest factor) and the tissue's consistent conductive properties make it possible for CK to achieve a reproducible, optimal tissue temperature for the critical time necessary to bring about the localized shrinkage of the collagen fibers.

Depth of procedure and effects
CK creates a purse-string effect that steepens the central cornea through a ring of application spots around the periphery of the cornea. Several studies have concluded that the depth of shrinkage determines the degree of corneal correction permanency. Because of the intrastromal delivery of RF energy, CK produces collagen shrinkage that encompasses 80% of the corneal thickness.

Info Refractec, Inc.
Customer Service: (800) 752-9544
Web site: http://www.refractec.com

Related medicine products :

1. Silicone Oil Cannula System - 20 Gauge
2. Silicone Oil Cannula System - 19 Gauge
3. SuperVu Galilean System
4. KOWA nonmyd 7 / VK-2 Digital Imaging System
5. KOWA nonmyd a-D / VK-2 Digital Imaging System
6. Refraction System RT-2100
7. Odyssey Phacoemulsification System
8. SIStem Phacoemulsification System
9. Precisionist Phacoemulsification System
10. Photon Laser Phacoemulsification System
11. Phaco-Emulsification System
Accurately tests for Nystagmus when rotated at 8-10 rpm. Drums are 10" high by 8" diameter. Light weight drum of professional quality with ball bearings for effortless spin mechanism. For use 24 to 3
Sterile squares of textured nylon foil for repair of the floor of the orbit.
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile
Segment stand magnifiers come complete with bar magnifier to achieve a higher magnification while still maintaining a wide binocular field of view.
Medicine Products:
(Date:9/8/2008)...aser scalpels, arthroscopic,surgery, genomic resea...rinary medicine is quickly expanding into new high...e benefit; it,s improving medicine for,people, too... care for their pets to,treat diseases like diabet... according to the American Veterinary Medical Asso...
(Date:9/8/2008)...zine examines Iraq and Afghanistan veterans, strug..., Washington, DC (PRWEB) S...by veterans of the Iraq and Afghanistan wars about... addiction disorders are featured in the current i...ublication of the National Council for Community B...
(Date:9/7/2008)...f older patients successfully treated for colorect...le to detect any recurrence of cancer. The study, ... , a peer-reviewed journal of the American Cancer ...monitoring of colorectal cancer survivors could af...y curative surgery for colorectal cancer have an i...
(Date:9/7/2008)... appear to lower a man,s PSA level, the blood biom...her a man is at risk of prostate cancer. , But t.... 8 in the journal Cancer , caution that men shou... prostate cancer just yet. , "We showed that me...rin and other non-steroidal anti-inflammatory drug...
Breaking Medicine News(10 mins):Health News:High-Tech Vet Medicine Saving Lives of Pets and People 2Health News:Helping Veterans in Our Communities 2Health News:Helping Veterans in Our Communities 3Health News:Many colorectal cancer survivors do not receive recommended follow-up care 2Health News:Common painkillers lower levels of prostate cancer biomarker 2
...ore functions in reproduction than merely being a ...ts that the semen from fertile men contains a mult...cle Stimulating Hormone) initiates ovulation. Some... role in the maintenance of pregnancy. The researc...
...boast of their first FDA-approved pill capable of ...y due to the creation// of a new molecule by a res...tified by the name TMC-114, and also known by the ...molecules that are still under creation by Arun Gh...
...guards and NHS red tape following the Alder Hey bo...dicines, according to researchers//. With restrict...perwork, and seemingly arbitrary judgments by ethi...eterred from getting studies up and running. Jenn...
...e health implication when tiny particles in the ai...er scientists demonstrated that when rats inhale//...ay and make it to many regions in the brain. This ...mental Health Perspectives. There were also eviden...
Other Medicine News:Health News:Finally, The First Ever Treatment for Drug-Resistant HIV 2Health News:Finally, The First Ever Treatment for Drug-Resistant HIV 3Health News:Finally, The First Ever Treatment for Drug-Resistant HIV 4Health News:Medical researchers being stifled by NHS Red tape 2Health News:Nano-sized inhaled particles traverse quickly from nose to brain 2
(Date:9/8/2008)...ept. 8 /- Novo Nordisk (NYS...data from a phase 3 clinical study,(LEAD(TM) 4) to...ociation,for the Study of Diabetes that demonstrat..., a human GLP-1 analog, to metformin and rosiglita... improved blood glucose lowering,(HbA1c), weight l...
(Date:9/5/2008)...TON, Fla., Sept. 5 /PRNewswire-USNewswire/ -- The ... recently awarded Florida,Atlantic University rese...sor and director of the Center for Molecular Biolo...lege of Science, and CHS,Resources LLC (CHS), $184...ercialization Assistance Grant program (SURECAG). ...
(Date:9/5/2008)... Demonstrates microRNAs Extracted From a Simple Bl...Clinical Biomarkers for a Wide Range of ...ary Technology, Rosetta Genomics is Currently Deve...Colon Cancer, REHOVOT, Israel and JERSEY CITY, Ne...setta Genomics, Ltd. (NASDQ: ROSG), a leader in,th...
(Date:9/4/2008)...a Published in ,The Lancet, and Presented at ESC C...esults from a new international,study, the GISSI H...ose of,omega-3 acid ethyl esters reduced all cause...lar reasons in patients with chronic heart,failure...ne version of ,The,Lancet, and were presented at t...
Breaking Medicine Technology:Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes 2Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes 3Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes 4Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes 5Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Lettuces Roots Lure Salmonella 3474 1Lettuces Roots Lure Salmonella 3474 2Lettuces Roots Lure Salmonella 3474 3Anticlotting drug found to be safe in sickle cell patients 3472 1Anticlotting drug found to be safe in sickle cell patients 3472 2MIT links gene to cholesterol 761 1MIT links gene to cholesterol 761 2Select Medical Corporation to Announce Third Quarter Results on Monday November 12 3470 1
...abetes Patients -, MONTREAL, March 26 /CNW/ - Co...ounced positive preliminary results from its,Pha...ment of Type 2,diabetes using the Company,s prop...tudy demonstrated that PC-DAC(TM):Exendin-4 was,...ce-weekly at each,of the dosing levels tested, l...
... from ECLIPSE, Largest Safety,Program of Intraveno... 2007 /PRNewswire-FirstCall/ -- Favorable,findings...ipine),compared to current intravenous antihyperte...sion -- a potentially harmful,elevation in blood p...- were presented for the first time at a late-brea...
Other Medicine Technology:PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 2PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 3PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 4Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 2Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 3Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 4Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 5